Table of Contents GBI Research Report Guidance 2 Executive Summary 3 Table of Contents 4 List of Tables 6 List of Figures 15 Introduction 18 Cardiovascular Disorders Report Coverage 18 Hypertension Overview 18 Dyslipidemia Overview 18 Thromboembolism Overview 18 Heart Failure Overview 18 Therapeutics Development 20 Hypertension 20 Dyslipidemia 22 Thromboembolism 24 Heart Failure 26 Therapeutics under Development by Companies 31 Hypertension 31 Dyslipidemia 35 Thromboembolism 39 Heart Failure 40 Therapeutics under Investigation by Universities/Institutes 47 Hypertension 47 Dyslipidemia 49 Thromboembolism 50 Heart Failure 50 Pipeline Products Glance 52 Hypertension 52 Dyslipidemia 55 Thromboembolism 58 Heart Failure 61 Products under Development by Companies 68 Hypertension 68 Dyslipidemia 75 Thromboembolism 79 Heart Failure 79 Products under Investigation by Universities/Institutes 86 Hypertension 86 Dyslipidemia 87 Thromboembolism 88 Heart Failure 88 Companies Involved in Therapeutics Development 90 Hypertension 90 Dyslipidemia 151 Thromboembolism 185 Heart Failure 192 Therapeutics Assessment 244 Hypertension 244 Dyslipidemia 265 Thromboembolism 281 Heart Failure 290 Dormant Projects 325 Hypertension 325 Dyslipidemia 335 Thromboembolism 343 Heart Failure 343 Discontinued Products 349 Hypertension 349 Dyslipidemia 351 Thromboembolism 353 Heart Failure 353 Product Development Milestones 356 Hypertension 356 Dyslipidemia 367 Thromboembolism 379 Heart Failure 396 Appendix 431 Methodology 431 Coverage 431 Secondary Research 431 Primary Research 431 Expert Panel Validation 431 Contact Us 432 Disclaimer 432

List of Tables Number of Products under Development for Hypertension 20 Number of Products under Development for Hypertension - Comparative Analysis 21 Number of Products under Development for Dyslipidemia 22 Number of Products under Development for Dyslipidemia - Comparative Analysis 23 Number of Products under Development for Thromboembolism 24 Number of Products under Development for Thromboembolism - Comparative Analysis 25 Number of Products under Development for Acute Heart Failure 26 Number of Products under Development for Congestive Heart Failure (Heart Failure) 27 Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis 28 Number of Products under Development for Chronic Heart Failure 29 Number of Products under Development for Chronic Heart Failure - Comparative Analysis 30 Number of Products under Development by Companies, Hypertension 31 Number of Products under Development by Companies, Dyslipidemia 36 Number of Products under Development by Companies, Thromboembolism 39 Number of Products under Development by Companies, Acute Heart Failure 40 Number of Products under Development by Companies, Congestive Heart Failure (Heart Failure) 42 Number of Products under Development by Companies, Chronic Heart Failure 46 Number of Products under Investigation by Universities/Institutes, Hypertension 48 Number of Products under Investigation by Universities/Institutes, Dyslipidemia 49 Number of Products under Investigation by Universities/Institutes, Thromboembolism 50 Number of Products under Investigation by Universities/Institutes, Congestive Heart Failure (Heart Failure) 51 Number of Products under Investigation by Universities/Institutes, Chronic Heart Failure 51 Comparative Analysis by Late Stage Development, Hypertension 52 Comparative Analysis by Clinical Stage Development, Hypertension 53 Comparative Analysis by Early Stage Development, Hypertension 54 Comparative Analysis by Late Stage Development, Dyslipidemia 55 Comparative Analysis by Clinical Stage Development, Dyslipidemia 56 Comparative Analysis by Early Stage Development, Dyslipidemia 57 Comparative Analysis by Unknown Stage Development, Dyslipidemia 58 Comparative Analysis by Late Stage Development, Thromboembolism 58 Comparative Analysis by Clinical Stage Development, Thromboembolism 59 Comparative Analysis by Early Stage Development, Thromboembolism 60 Comparative Analysis by Late Stage Development, Acute Heart Failure 61 Comparative Analysis by Clinical Stage Development, Acute Heart Failure 61 Comparative Analysis by Early Stage Development, Acute Heart Failure 62 Comparative Analysis by Late Stage Development, Congestive Heart Failure (Heart Failure) 62 Comparative Analysis by Clinical Stage Development, Congestive Heart Failure (Heart Failure) 63 Comparative Analysis by Early Stage Development, Congestive Heart Failure (Heart Failure) 64 Comparative Analysis by Unknown Stage Development, Congestive Heart Failure (Heart Failure) 65 Comparative Analysis by Late Stage Development, Chronic Heart Failure 65 Comparative Analysis by Clinical Stage Development, Chronic Heart Failure 66 Comparative Analysis by Early Stage Development, Chronic Heart Failure 67 Products under Development by Companies, Hypertension 68 Products under Development by Companies, Dyslipidemia 75 Products under Development by Companies, Thromboembolism 79 Products under Development by Companies, Acute Heart Failure 79 Products under Development by Companies, Congestive Heart Failure (Heart Failure) 80 Products under Development by Companies, Chronic Heart Failure 85 Products under Investigation by Universities/Institutes, Hypertension 86 Products under Investigation by Universities/Institutes, Dyslipidemia 87 Products under Investigation by Universities/Institutes, Thromboembolism 88 Products under Investigation by Universities/Institutes, Congestive Heart Failure (Heart Failure) 88 Products under Investigation by Universities/Institutes, Chronic Heart Failure 89 Hypertension - Pipeline by A1M Pharma AB 90 Hypertension - Pipeline by AbbVie Inc 90 Hypertension - Pipeline by Actelion Ltd 91 Hypertension - Pipeline by Afferent Pharmaceuticals Inc 91 Hypertension - Pipeline by Alnylam Pharmaceuticals Inc 92 Hypertension - Pipeline by Anacor Pharmaceuticals Inc 93 Hypertension - Pipeline by AnGes MG Inc 94 Hypertension - Pipeline by APT Therapeutics Inc 94 Hypertension - Pipeline by Arena Pharmaceuticals Inc 95 Hypertension - Pipeline by Ascendis Pharma A/S 96 Hypertension - Pipeline by Asklepion Pharmaceuticals LLC 97 Hypertension - Pipeline by AVEO Pharmaceuticals Inc 97 Hypertension - Pipeline by Bayer AG 98 Hypertension - Pipeline by Bial - Portela & Ca SA 98 Hypertension - Pipeline by Biolab Farmaceutica Ltda 99 Hypertension - Pipeline by BioRestorative Therapies Inc 99 Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd 100 Hypertension - Pipeline by Cellceutix Corp 100 Hypertension - Pipeline by Celsion Corp 101 Hypertension - Pipeline by Celtaxsys Inc 101 Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp 102 Hypertension - Pipeline by CJ HealthCare Corp 102 Hypertension - Pipeline by Complexa Inc 103 Hypertension - Pipeline by Conatus Pharmaceuticals Inc 103 Hypertension - Pipeline by Corion Biotech Srl 104 Hypertension - Pipeline by Cumberland Pharmaceuticals Inc 104 Hypertension - Pipeline by Cytokinetics Inc 105 Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd 106 Hypertension - Pipeline by Daiichi Sankyo Company Ltd 107 Hypertension - Pipeline by DiaMedica Inc 107 Hypertension - Pipeline by Eli Lilly and Company 108 Hypertension - Pipeline by Esperion Therapeutics Inc 108 Hypertension - Pipeline by F. Hoffmann-La Roche Ltd 109 Hypertension - Pipeline by Ferring International Center SA 109 Hypertension - Pipeline by Galectin Therapeutics Inc 110 Hypertension - Pipeline by Genextra Spa 110 Hypertension - Pipeline by Gilead Sciences Inc 111 Hypertension - Pipeline by GlaxoSmithKline Plc 112 Hypertension - Pipeline by Glenveigh Medical LLC 112 Hypertension - Pipeline by HanAll Biopharma Co Ltd 113 Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd 114 Hypertension - Pipeline by HitGen LTD 114 Hypertension - Pipeline by Innopharmax Inc 115 Hypertension - Pipeline by Insmed Inc 115 Hypertension - Pipeline by INVENT Pharmaceuticals Inc 116 Hypertension - Pipeline by Ionis Pharmaceuticals Inc 116 Hypertension - Pipeline by Ironwood Pharmaceuticals Inc 117 Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd 118 Hypertension - Pipeline by Johnson & Johnson 119 Hypertension - Pipeline by JW Pharmaceutical Corp 120 Hypertension - Pipeline by Kowa Company Ltd 120 Hypertension - Pipeline by Leading BioSciences Inc 121 Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd 121 Hypertension - Pipeline by Les Laboratoires Servier SAS 122 Hypertension - Pipeline by LFB SA 122 Hypertension - Pipeline by LG Life Science LTD 123 Hypertension - Pipeline by LinXis BV 123 Hypertension - Pipeline by Liquidia Technologies Inc 124 Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd 124 Hypertension - Pipeline by MannKind Corp 125 Hypertension - Pipeline by Mast Therapeutics Inc 125 Hypertension - Pipeline by Merck & Co Inc 126 Hypertension - Pipeline by Mezzion Pharma Co Ltd 126 Hypertension - Pipeline by miRagen Therapeutics Inc 127 Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp 127 Hypertension - Pipeline by Morphogen-IX Ltd 128 Hypertension - Pipeline by Neurim Pharmaceuticals Ltd 128 Hypertension - Pipeline by Nippon Kayaku Co Ltd 129 Hypertension - Pipeline by Nippon Shinyaku Co Ltd 130 Hypertension - Pipeline by Novartis AG 131 Hypertension - Pipeline by Noxamet Ltd 131 Hypertension - Pipeline by Omeros Corp 132 Hypertension - Pipeline by Peloton Therapeutics Inc 132 Hypertension - Pipeline by Pfizer Inc 133 Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc 133 Hypertension - Pipeline by Pluristem Therapeutics Inc 134 Hypertension - Pipeline by Polyphor Ltd 134 Hypertension - Pipeline by Proteo Inc 135 Hypertension - Pipeline by Pulmokine Inc 135 Hypertension - Pipeline by Quantum Genomics SA 136 Hypertension - Pipeline by Reata Pharmaceuticals Inc 136 List of Figures Number of Products under Development for Hypertension 20 Number of Products under Development for Hypertension - Comparative Analysis 21 Number of Products under Development for Dyslipidemia 22 Number of Products under Development for Dyslipidemia - Comparative Analysis 23 Number of Products under Development for Thromboembolism 24 Number of Products under Development for Thromboembolism - Comparative Analysis 25 Number of Products under Development for Acute Heart Failure 26 Number of Products under Development for Congestive Heart Failure (Heart Failure) 27 Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis 28 Number of Products under Development for Chronic Heart Failure 29 Number of Products under Development for Chronic Heart Failure - Comparative Analysis 30 Number of Products under Development by Companies, Hypertension 31 Number of Products under Development by Companies, Dyslipidemia 35 Number of Products under Development by Companies, Thromboembolism 39 Number of Products under Development by Companies, Acute Heart Failure 40 Number of Products under Development by Companies, Congestive Heart Failure (Heart Failure) 41 Number of Products under Development by Companies, Chronic Heart Failure 45 Number of Products under Investigation by Universities/Institutes, Hypertension 47 Number of Products under Investigation by Universities/Institutes, Dyslipidemia 49 Number of Products under Investigation by Universities/Institutes, Congestive Heart Failure (Heart Failure) 50 Comparative Analysis by Late Stage Development, Hypertension 52 Comparative Analysis by Clinical Stage Development, Hypertension 53 Comparative Analysis by Early Stage Products, Hypertension 54 Comparative Analysis by Late Stage Development, Dyslipidemia 55 Comparative Analysis by Clinical Stage Development, Dyslipidemia 56 Comparative Analysis by Early Stage Products, Dyslipidemia 57 Comparative Analysis by Late Stage Development, Thromboembolism 58 Comparative Analysis by Clinical Stage Development, Thromboembolism 59 Comparative Analysis by Early Stage Products, Thromboembolism 60 Comparative Analysis by Clinical Stage Development, Acute Heart Failure 61 Comparative Analysis by Late Stage Development, Congestive Heart Failure (Heart Failure) 62 Comparative Analysis by Clinical Stage Development, Congestive Heart Failure (Heart Failure) 63 Comparative Analysis by Early Stage Products, Congestive Heart Failure (Heart Failure) 64 Comparative Analysis by Clinical Stage Development, Chronic Heart Failure 66 Comparative Analysis by Early Stage Products, Chronic Heart Failure 67 Assessment by Monotherapy Products, Hypertension 244 Assessment by Combination Products, Hypertension 245 Number of Products by Top 10 Targets, Hypertension 246 Number of Products by Stage and Top 10 Targets, Hypertension 246 Number of Products by Top 10 Mechanism of Actions, Hypertension 254 Number of Products by Stage and Top 10 Mechanism of Actions, Hypertension 254 Number of Products by Top 10 Routes of Administration, Hypertension 262 Number of Products by Stage and Top 10 Routes of Administration, Hypertension 262 Number of Products by Top 10 Molecule Types, Hypertension 264 Number of Products by Stage and Top 10 Molecule Types, Hypertension 264 Assessment by Monotherapy Products, Dyslipidemia 265 Assessment by Combination Products, Dyslipidemia 267 Number of Products by Top 10 Targets, Dyslipidemia 268 Number of Products by Stage and Top 10 Targets, Dyslipidemia 268 Number of Products by Top 10 Mechanism of Actions, Dyslipidemia 273 Number of Products by Stage and Top 10 Mechanism of Actions, Dyslipidemia 273 Number of Products by Routes of Administration, Dyslipidemia 278 Number of Products by Stage and Routes of Administration, Dyslipidemia 278 Number of Products by Molecule Types, Dyslipidemia 280 Number of Products by Stage and Molecule Types, Dyslipidemia 280 Assessment by Monotherapy Products, Thromboembolism 281 Number of Products by Targets, Thromboembolism 283 Number of Products by Stage and Targets, Thromboembolism 283 Number of Products by Mechanism of Actions, Thromboembolism 285 Number of Products by Stage and Mechanism of Actions, Thromboembolism 285 Number of Products by Routes of Administration, Thromboembolism 287 Number of Products by Stage and Routes of Administration, Thromboembolism 287 Number of Products by Molecule Types, Thromboembolism 289 Number of Products by Stage and Molecule Types, Thromboembolism 289 Assessment by Monotherapy Products, Acute Heart Failure 290 Number of Products by Top 10 Targets, Acute Heart Failure 292 Number of Products by Stage and Top 10 Targets, Acute Heart Failure 292 Number of Products by Top 10 Mechanism of Actions, Acute Heart Failure 294 Number of Products by Stage and Top 10 Mechanism of Actions, Acute Heart Failure 294 Number of Products by Routes of Administration, Acute Heart Failure 296 Number of Products by Stage and Routes of Administration, Acute Heart Failure 296 Number of Products by Molecule Types, Acute Heart Failure 298 Number of Products by Stage and Molecule Types, Acute Heart Failure 298 Assessment by Monotherapy Products, Congestive Heart Failure (Heart Failure) 299 Number of Products by Top 10 Targets, Congestive Heart Failure (Heart Failure) 300 Number of Products by Stage and Top 10 Targets, Congestive Heart Failure (Heart Failure) 301 Number of Products by Top 10 Mechanism of Actions, Congestive Heart Failure (Heart Failure) 307 Number of Products by Stage and Top 10 Mechanism of Actions, Congestive Heart Failure (Heart Failure) 307 Number of Products by Top 10 Routes of Administration, Congestive Heart Failure (Heart Failure) 313 Number of Products by Stage and Top 10 Routes of Administration, Congestive Heart Failure (Heart Failure) 313 Number of Products by Top 10 Molecule Types, Congestive Heart Failure (Heart Failure) 315 Number of Products by Stage and Top 10 Molecule Types, Congestive Heart Failure (Heart Failure) 315 Assessment by Monotherapy Products, Chronic Heart Failure 316 Number of Products by Top 10 Targets, Chronic Heart Failure 318 Number of Products by Stage and Top 10 Targets, Chronic Heart Failure 318 Number of Products by Top 10 Mechanism of Actions, Chronic Heart Failure 320 Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Heart Failure 320 Number of Products by Routes of Administration, Chronic Heart Failure 322 Number of Products by Stage and Routes of Administration, Chronic Heart Failure 322 Number of Products by Molecule Types, Chronic Heart Failure 324 Number of Products by Stage and Molecule Types, Chronic Heart Failure 324